Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study

Tianyan Hu; Bélène Podmore; Rosemarie Barnett; Dominik Beier; Wolfgang Galetzka; Nawab Qizilbash; Dennis Haeckl; Timo Boellinger; Jessica Weaver

doi:https://doi.org/10.1186/s41479-023-00105-9

Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study

Tianyan Hu, Bélène Podmore, Rosemarie Barnett, Dominik Beier, Wolfgang Galetzka, Nawab Qizilbash, Dennis Haeckl, Timo Boellinger, Jessica Weaver

Department for Health

Research output: Contribution to journal › Article › peer-review

Abstract

Background
Since the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children
Methods
A nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged
Results
During 2014–2019, 916,805 children aged
Conclusions
The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014–2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.

Original language	English
Article number	7 (2023)
Journal	Pneumonia
DOIs	https://doi.org/10.1186/s41479-023-00105-9
Publication status	Published - 25 Mar 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1186/s41479-023-00105-9Licence: CC BY

Cite this

@article{d9ceb4043e72451e825c952b9f7378fd,

title = "Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study",

abstract = "BackgroundSince the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children MethodsA nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged Results During 2014–2019, 916,805 children aged Conclusions The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014–2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.",

author = "Tianyan Hu and B{\'e}l{\`e}ne Podmore and Rosemarie Barnett and Dominik Beier and Wolfgang Galetzka and Nawab Qizilbash and Dennis Haeckl and Timo Boellinger and Jessica Weaver",

note = "Funding This research was sponsored and funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Availability of data and materials The data that support the fndings of this study are stored within the Institute for Applied Health Research Berlin GmbH (InGef, www.InGef.de). Restrictions apply to the availability of these data, and they are not publicly available. Access to patient-level data is not possible and all analyses must be conducted by InGef. Requests for bespoke analyses/ aggregate results are reviewed and approved by InGef.",

year = "2023",

month = mar,

day = "25",

doi = "https://doi.org/10.1186/s41479-023-00105-9",

language = "English",

journal = "Pneumonia",

issn = "2200-6133",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019

T2 - a retrospective cohort study

AU - Hu, Tianyan

AU - Podmore, Bélène

AU - Barnett, Rosemarie

AU - Beier, Dominik

AU - Galetzka, Wolfgang

AU - Qizilbash, Nawab

AU - Haeckl, Dennis

AU - Boellinger, Timo

AU - Weaver, Jessica

N1 - Funding This research was sponsored and funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Availability of data and materials The data that support the fndings of this study are stored within the Institute for Applied Health Research Berlin GmbH (InGef, www.InGef.de). Restrictions apply to the availability of these data, and they are not publicly available. Access to patient-level data is not possible and all analyses must be conducted by InGef. Requests for bespoke analyses/ aggregate results are reviewed and approved by InGef.

PY - 2023/3/25

Y1 - 2023/3/25

N2 - BackgroundSince the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children MethodsA nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged Results During 2014–2019, 916,805 children aged Conclusions The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014–2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.

AB - BackgroundSince the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children MethodsA nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged Results During 2014–2019, 916,805 children aged Conclusions The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014–2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.

U2 - https://doi.org/10.1186/s41479-023-00105-9

DO - https://doi.org/10.1186/s41479-023-00105-9

M3 - Article

SN - 2200-6133

JO - Pneumonia

JF - Pneumonia

M1 - 7 (2023)

ER -

Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this